Recent advances in tumor targeting via EPR effect for cancer treatment
Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent
in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy …
in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy …
Progress, challenges, and future of nanomedicine
Nanotherapeutics exhibit unique advantages in clinical outcomes compared with
conventional small molecular drugs. The past three decades have seen intensive research …
conventional small molecular drugs. The past three decades have seen intensive research …
Reactive oxygen species‐regulating strategies based on nanomaterials for disease treatment
Reactive oxygen species (ROS) play an essential role in physiological and pathological
processes. Studies on the regulation of ROS for disease treatments have caused wide …
processes. Studies on the regulation of ROS for disease treatments have caused wide …
Tumor targeting via EPR: Strategies to enhance patient responses
The tumor accumulation of nanomedicines relies on the enhanced permeability and
retention (EPR) effect. In the last 5–10 years, it has been increasingly recognized that there …
retention (EPR) effect. In the last 5–10 years, it has been increasingly recognized that there …
Nanobodies: next generation of cancer diagnostics and therapeutics
The development of targeted medicine has greatly expanded treatment options and spurred
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
P Bannas, J Hambach, F Koch-Nolte - Frontiers in immunology, 2017 - frontiersin.org
Monoclonal antibodies have revolutionized cancer therapy. However, delivery to tumor cells
in vivo is hampered by the large size (150 kDa) of conventional antibodies. The minimal …
in vivo is hampered by the large size (150 kDa) of conventional antibodies. The minimal …
Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review
N Muhamad, T Plengsuriyakarn… - International journal of …, 2018 - Taylor & Francis
Patients treated with conventional cancer chemotherapy suffer from side effects of the drugs
due to non-selective action of chemotherapeutic drugs to normal cells. Active targeting …
due to non-selective action of chemotherapeutic drugs to normal cells. Active targeting …
Ligand‐installed nanocarriers toward precision therapy
Abstract Development of drug‐delivery systems that selectively target neoplastic cells has
been a major goal of nanomedicine. One major strategy for achieving this milestone is to …
been a major goal of nanomedicine. One major strategy for achieving this milestone is to …
Hybrid cell membrane-coated nanoparticles: a multifunctional biomimetic platform for cancer diagnosis and therapy
HY Chen, J Deng, Y Wang, CQ Wu, X Li, HW Dai - Acta biomaterialia, 2020 - Elsevier
Biomimetic nanotechnology through camouflaging synthetic nanoparticles (NPs) with
natural cell membranes, which bestows with immune evasion and superior targeting …
natural cell membranes, which bestows with immune evasion and superior targeting …
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
E Pérez-Herrero, A Fernández-Medarde - European journal of …, 2015 - Elsevier
Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases.
It is characterized by uncontrolled cell proliferation and an absence of cell death that, except …
It is characterized by uncontrolled cell proliferation and an absence of cell death that, except …